Recruiting

Genetic Testing

Sponsor:

National Cancer Institute (NCI)

Code:

NCT00050752

Conditions

Renal Tumor Histology

Cutaneous Leiomyoma

Kidney Cancer

Eligibility Criteria

Sex: All

Age: 2+

Healthy Volunteers: Accepted

Study Details

Brief summary:

This study will investigate what causes hereditary leiomyomatosis renal (kidney) cell cancer, or HLRCC, and how the disease is related to the development of kidney tumors. Leiomyomas are benign (non-cancerous) tumors arising from smooth muscle. HLRCC can cause various health problems. Some people develop red bumps on their skin that can be painful at times. Some women with HLRCC can develop leiomyomas of the uterus. In some families, people with HLRCC develop kidney tumors. This study will try to determine:

  • What gene changes (mutations) cause HLRCC
  • What kind of kidney tumors develop in HLRCC and how they grow
  • What the chance is that a person with HLRCC will develop a kidney tumor

People with known or suspected HLRCC (and their family members of any age) may be eligible for this study. This includes people in families in which one or more members has skin leiomyoma and kidney cancer; skin leiomyoma and uterine leiomyoma; multiple skin leiomyomas; kidney cancer and uterine leiomyomas, or kidney cancer consistent with HLRCC, including, but not limited to, collecting duct or papillary, type II. Candidates will be screened with a physical examination, family history, and, for affected family members, a review of medical records, including pathology slides and computed tomography (CT) or magnetic resonance imaging (MRI) scans.

Participants will undergo tests and procedures that may include the following:

  • Review of medical records, x-rays, and tissue slides
  • Physical examination and family history
  • Skin examination
  • Gynecological examination for women
  • Interviews with a cancer doctor, cancer nurses, kidney surgeon, and genetic counselor
  • Blood tests for:

1. Genetic research to identify the gene responsible for HLRCC
2. Evaluation of liver, kidney, heart, pancreas, and thyroid function
3. Complete blood count and clotting profile
4. Pregnancy test for pre-menopausal women
5. PSA test for prostate cancer in men over age 40
  • CT or MRI scans (for participants 15 years of age and older only)
  • Skin biopsy (surgical removal of a small sample of skin tissue)
  • Cheek swab or mouth rinse to collect cells for genetic analysis
  • Medical photographs of lesions
  • Questionnaire

When the tests are completed, participants will discuss the results with a doctor and possibly a genetic nurse or genetic counselor. The genetic findings will not be revealed to participants because their meaning and implications may not yet be understood. Participants may be asked to return to NIH from every 3 months to every 3 years, depending on their condition, for follow-up examinations and tests.

...

Conditions

Renal Tumor Histology

Cutaneous Leiomyoma

Kidney Cancer

Study ID

NCT00050752

Start date

Feb 24, 2003

Status verified date

Jun 17, 2026

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 2+

Healthy Volunteers: Accepted

  • INCLUSION CRITERIA:
  • Individuals suspected or known to have phenotype or genotype suggestive of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC), such as:

  • Cutaneous leiomyoma and kidney cancer; or
  • Cutaneous leiomyoma and uterine leiomyoma; or
  • Multiple cutaneous leiomyoma; or
  • Kidney cancer and uterine leiomyomata; or
  • Renal tumor histology consistent with HLRCC including, but not limited to: Collecting Duct and/or Papillary, Type II
  • All participants and parents/guardians, for children younger than 18 years of age, must sign an informed consent document indicating their understanding of the investigational nature and the risks of this study before any protocol related studies are performed.
  • Participants must be >= 2 years of age.
  • A relative (related by blood) of an individual with a confirmed or suspected diagnosis of HLRCC.

EXCLUSION CRITERIA:

None

Study Design

Enrollment

1130 participants

Anticipated

Interventions and Outcome Measures

Arms

1 / Individuals

Individuals with known or suspected Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC)

2 / Family Members

Family members (related by blood) of individuals who have or are suspected of having Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC)

3 / Non-Biologic Family Members

Spouses enrolled primarily for linkage analysis (Spouses have been removed from the inclusion criteria for this study. This closed cohort is for spouses previously enrolled on study.)

Primary outcome measure

  • Determine the incidence and characteristics of HLRCC-associated fumarate hydratase gene mutations. [ Time Frame: on-going ]
  • Determine the clinical manifestations of HLRCC [ Time Frame: on-going ]
  • Determine if other genes cause HLRCC. [ Time Frame: on-going ]
  • Determine genotype/phenotype correlations. [ Time Frame: on-going ]
  • Define the types and characteristics (including patterns of growth) of renal cancer associated with HLRCC. [ Time Frame: on-going ]
  • Define the risk of developing renal cancer, cutaneous leiomyoma and uterine leiomyoma in this hereditary cancer syndrome. [ Time Frame: on-going ]

Central Contacts and Locations

Central contacts

Locations

National Institutes of Health Clinical Center

Recruiting

Bethesda, Maryland, United States, 20892

Contacts

For more information at the NIH Clinical Center contact National Cancer Institute Referral Office

888-624-1937

More Information

Sponsor

National Cancer Institute (NCI)

Last update posted

Aug 31, 2026

Last verified

Jun 17, 2026

Keywords

  • Renal Cancer
  • Hereditary Leiomyomatosis
  • Uterine Fibroid
  • Cutaneous Leiomyoma
  • Natural History

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2026-08-31.